Autolus Therapeutics (AUTL) Cash from Financing Activities (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Cash from Financing Activities for 9 consecutive years, with -$1.8 million the latest figure, recorded in Q4 2025.

• Quarterly Cash from Financing Activities fell 105.99% year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.3 million (down 100.74% YoY) and the FY2025 annual result came in at -$4.3 million, down 100.74% from the prior year.
• Cash from Financing Activities eased to -$1.8 million in Q4 2025 per AUTL's latest filing, from -$1.8 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for AUTL reached as high as $561.4 million in Q1 2024 and fell as low as -$2.1 million in Q2 2024.
• A 5-year average of $60.7 million and a median of $13500.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 69000.0% — and 2024, when it surged 130365.22%.
• Year by year, Cash from Financing Activities stood at $147.4 million in 2021, then jumped by 51.62% to $223.5 million in 2022, then sank by 99.99% to $23000.0 in 2023, then jumped by 130365.22% to $30.0 million in 2024, then sank by 105.99% to -$1.8 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.8 million, -$1.8 million, and -$768000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.